Invention Grant
- Patent Title: Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
-
Application No.: US15504854Application Date: 2015-08-19
-
Publication No.: US10562900B2Publication Date: 2020-02-18
- Inventor: Meiyu Geng , Lei Liu , Lei Jiang , Min Huang , Chuantao Zha , Jing Ai , Lei Wang , Jianhua Cao , Jian Ding
- Applicant: Shanghai Haihe Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Applicant Address: CN Shanghai CN Shanghai
- Assignee: Shanghai Haihe Pharmaceutical Co., Ltd.,Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Current Assignee: Shanghai Haihe Pharmaceutical Co., Ltd.,Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Current Assignee Address: CN Shanghai CN Shanghai
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: CN201410409467 20140819; CN201510073179 20150211
- International Application: PCT/CN2015/087556 WO 20150819
- International Announcement: WO2016/026445 WO 20160225
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D231/56 ; C07D519/00 ; C07D401/12 ; C07D471/04 ; C07D403/12 ; C07D498/04 ; C07D401/14 ; C07D405/14 ; C07D417/12 ; A61K31/416 ; A61K31/496
Abstract:
The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
Public/Granted literature
- US20170275291A1 INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF Public/Granted day:2017-09-28
Information query
